ZOMETA® - Threat of SREs From Bone Metastases Increases As New Treatments in RCC Extend Survival

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

Page

1 2

As new treatments extend survival, the threat of SREs increases

Median progression-free survival (PFS) for patients with advanced renal cell carcinoma treated with sunitinib is 11.8 months (median survival not yet reported)⁴
Without treatment, the time to first SRE in patients with advanced renal cell carcinoma is less than 2.5 months²

Median time to first SRE vs PFS in advanced renal cell carcinoma^2,4

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.